Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer
- PMID: 34450047
- PMCID: PMC8367743
- DOI: 10.1016/j.ccell.2021.08.001
Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer
Comment on
-
COVID-19 and Cancer: Current Challenges and Perspectives.Cancer Cell. 2020 Nov 9;38(5):629-646. doi: 10.1016/j.ccell.2020.09.018. Epub 2020 Oct 1. Cancer Cell. 2020. PMID: 33049215 Free PMC article. Review.
-
Immune responses to COVID-19 vaccines in patients with cancer: Promising results and a note of caution.Cancer Cell. 2021 Aug 9;39(8):1045-1047. doi: 10.1016/j.ccell.2021.07.001. Epub 2021 Jul 3. Cancer Cell. 2021. PMID: 34242573 Free PMC article.
-
Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies.Cancer Cell. 2021 Aug 9;39(8):1031-1033. doi: 10.1016/j.ccell.2021.07.012. Epub 2021 Jul 22. Cancer Cell. 2021. PMID: 34331856 Free PMC article. No abstract available.
-
Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer.Cancer Cell. 2021 Aug 9;39(8):1034-1036. doi: 10.1016/j.ccell.2021.07.016. Epub 2021 Jul 27. Cancer Cell. 2021. PMID: 34348121 Free PMC article. No abstract available.
References
-
- Ehmsen S., Asmussen A., Jeppesen S.S., Nilsson A.C., Østerlev S., Vestergaard H., Justesen U.S., Johansen I.S., Frederiksen H., Ditzel H.J. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer. Cancer Cell. 2021;39 doi: 10.1016/j.ccell.2021.07.016. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous